309 related articles for article (PubMed ID: 28415765)
1. Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines.
Libouban MAA; de Roos JADM; Uitdehaag JCM; Willemsen-Seegers N; Mainardi S; Dylus J; de Man J; Tops B; Meijerink JPP; Storchová Z; Buijsman RC; Medema RH; Zaman GJR
Oncotarget; 2017 Jun; 8(24):38309-38325. PubMed ID: 28415765
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.
Maia AR; de Man J; Boon U; Janssen A; Song JY; Omerzu M; Sterrenburg JG; Prinsen MB; Willemsen-Seegers N; de Roos JA; van Doornmalen AM; Uitdehaag JC; Kops GJ; Jonkers J; Buijsman RC; Zaman GJ; Medema RH
Ann Oncol; 2015 Oct; 26(10):2180-92. PubMed ID: 26153498
[TBL] [Abstract][Full Text] [Related]
3. TC Mps1 12, a novel Mps1 inhibitor, suppresses the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instability.
Choi M; Min YH; Pyo J; Lee CW; Jang CY; Kim JE
Br J Pharmacol; 2017 Jun; 174(12):1810-1825. PubMed ID: 28299790
[TBL] [Abstract][Full Text] [Related]
4. Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition.
Jemaà M; Manic G; Lledo G; Lissa D; Reynes C; Morin N; Chibon F; Sistigu A; Castedo M; Vitale I; Kroemer G; Abrieu A
Oncotarget; 2016 Jan; 7(1):885-901. PubMed ID: 26637805
[TBL] [Abstract][Full Text] [Related]
5. Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity.
Uitdehaag JCM; de Man J; Willemsen-Seegers N; Prinsen MBW; Libouban MAA; Sterrenburg JG; de Wit JJP; de Vetter JRF; de Roos JADM; Buijsman RC; Zaman GJR
J Mol Biol; 2017 Jul; 429(14):2211-2230. PubMed ID: 28539250
[TBL] [Abstract][Full Text] [Related]
6. Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability.
Stratford JK; Yan F; Hill RA; Major MB; Graves LM; Der CJ; Yeh JJ
PLoS One; 2017; 12(4):e0174863. PubMed ID: 28380042
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
Mason JM; Wei X; Fletcher GC; Kiarash R; Brokx R; Hodgson R; Beletskaya I; Bray MR; Mak TW
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3127-3132. PubMed ID: 28270606
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis underlying resistance to Mps1/TTK inhibitors.
Koch A; Maia A; Janssen A; Medema RH
Oncogene; 2016 May; 35(19):2518-28. PubMed ID: 26364596
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255
[TBL] [Abstract][Full Text] [Related]
10. Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer.
Thu KL; Silvester J; Elliott MJ; Ba-Alawi W; Duncan MH; Elia AC; Mer AS; Smirnov P; Safikhani Z; Haibe-Kains B; Mak TW; Cescon DW
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1570-E1577. PubMed ID: 29378962
[TBL] [Abstract][Full Text] [Related]
11. Chromosomal instability upregulates interferon in acute myeloid leukemia.
Jin N; Lera RF; Yan RE; Guo F; Oxendine K; Horner VL; Hu Y; Wan J; Mattison RJ; Weaver BA; Burkard ME
Genes Chromosomes Cancer; 2020 Nov; 59(11):627-638. PubMed ID: 32557940
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy.
Faisal A; Mak GWY; Gurden MD; Xavier CPR; Anderhub SJ; Innocenti P; Westwood IM; Naud S; Hayes A; Box G; Valenti MR; De Haven Brandon AK; O'Fee L; Schmitt J; Woodward HL; Burke R; vanMontfort RLM; Blagg J; Raynaud FI; Eccles SA; Hoelder S; Linardopoulos S
Br J Cancer; 2017 Apr; 116(9):1166-1176. PubMed ID: 28334731
[TBL] [Abstract][Full Text] [Related]
13. TTK Inhibitors as a Targeted Therapy for
Zaman GJR; de Roos JADM; Libouban MAA; Prinsen MBW; de Man J; Buijsman RC; Uitdehaag JCM
Mol Cancer Ther; 2017 Nov; 16(11):2609-2617. PubMed ID: 28751540
[TBL] [Abstract][Full Text] [Related]
14. Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs.
Tannous BA; Kerami M; Van der Stoop PM; Kwiatkowski N; Wang J; Zhou W; Kessler AF; Lewandrowski G; Hiddingh L; Sol N; Lagerweij T; Wedekind L; Niers JM; Barazas M; Nilsson RJ; Geerts D; De Witt Hamer PC; Hagemann C; Vandertop WP; Van Tellingen O; Noske DP; Gray NS; Würdinger T
J Natl Cancer Inst; 2013 Sep; 105(17):1322-31. PubMed ID: 23940287
[TBL] [Abstract][Full Text] [Related]
15. Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
Sugimoto Y; Sawant DB; Fisk HA; Mao L; Li C; Chettiar S; Li PK; Darby MV; Brueggemeier RW
Bioorg Med Chem; 2017 Apr; 25(7):2156-2166. PubMed ID: 28259529
[TBL] [Abstract][Full Text] [Related]
16. Structural basis of reversine selectivity in inhibiting Mps1 more potently than aurora B kinase.
Hiruma Y; Koch A; Dharadhar S; Joosten RP; Perrakis A
Proteins; 2016 Dec; 84(12):1761-1766. PubMed ID: 27699881
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma.
Szymiczek A; Carbone M; Pastorino S; Napolitano A; Tanji M; Minaai M; Pagano I; Mason JM; Pass HI; Bray MR; Mak TW; Yang H
Oncogene; 2017 Nov; 36(46):6501-6507. PubMed ID: 28759042
[TBL] [Abstract][Full Text] [Related]
18. Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective.
Wang S; Zhang M; Liang D; Sun W; Zhang C; Jiang M; Liu J; Li J; Li C; Yang X; Zhou X
Eur J Med Chem; 2019 Aug; 175():247-268. PubMed ID: 31121430
[TBL] [Abstract][Full Text] [Related]
19. TTK inhibitor promotes radiosensitivity of liver cancer cells through p21.
Zhang H; Yao W; Zhang M; Lu Y; Tang J; Jiang M; Mou X; You G; Liang X
Biochem Biophys Res Commun; 2021 Apr; 550():84-91. PubMed ID: 33689884
[TBL] [Abstract][Full Text] [Related]
20. Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.
Huang M; Huang Y; Guo J; Yu L; Chang Y; Wang X; Luo J; Huang Y; Tu Z; Lu X; Xu Y; Zhang Z; Zhang Z; Ding K
Eur J Med Chem; 2021 Feb; 211():113023. PubMed ID: 33248853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
